Assess long term persistence of a primary dose of GSK Biologicals' meningococcal vaccine 134612 versus one dose of Mencevax ACWY in healthy adolescents/young adults (15 to 19 years at vaccination).

Trial Profile

Assess long term persistence of a primary dose of GSK Biologicals' meningococcal vaccine 134612 versus one dose of Mencevax ACWY in healthy adolescents/young adults (15 to 19 years at vaccination).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 polysaccharide (Primary) ; Meningococcal vaccine groups A C W-135 polysaccharide
  • Indications Meningococcal infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Feb 2010 Actual end date (May 2009) and actual number of patients (42) added as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top